Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient.
Introduction: Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. Case report: We report the case of a patient who developed unu...
| Publicado en: | Journal of Oncology Pharmacy Practice Vol. 28; no. 4; pp. 995 - 998 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Sage Publications Inc.
Jun2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156580223&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156580223 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10781552 0JI jtl: Journal of Oncology Pharmacy Practice issn: 10781552 maglogo: Y pubinfo: dt: Jun2022 vid: 28 iid: 4 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 156580223 154877563 156580223 156580223 10.1177/10781552211073802 156580223 ppf: 995 ppct: 3 formats: tig: atl: Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient. aug: au: Nefzi, Issad Yahyaoui, Yosra Letaief, Feriel Ghammem, Nour Gabsi, Azza Ayadi, Mouna Mezlini, Amel affil: Department of Medical Oncology, Salah Azaiez Institute, 59075 University of Tunis El Manar, Tunis, Tunisia sug: subj: Sarcoma, Ewing's Diagnosis Sarcoma, Ewing's Drug Therapy Granulocyte Colony-Stimulating Factor Therapeutic Use Granulocyte Colony-Stimulating Factor Adverse Effects Skin Pathology Skin Diseases, Vesiculobullous Diagnosis Male Adult Chemotherapy, Cancer Drug Hypersensitivity Biopsy Adult: 19-44 years Male ab: Introduction: Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. Case report: We report the case of a patient who developed unusual, non-commonly reported adverse toxidermy to filgrastim. At first the eruption was limited to the lower members and genetics organs. Then it slowly spread across the whole body presenting as a polymorphic exanthematous-pustulosis lesions. Management & Outcome: A cutaneous biopsy was done, identifying a toxidermy modified by systemic treatment. A pharmacological study linked the role of filgrastim to these lesions. After switching from filgrastim to lénograstim, his lesions are completely gone and haven't flared up again. Thus, clearly imputing the use of filgrastim. Discussion: The cutaneous reaction that has reported with use of GSCF are sweet syndrome, erythema nodosum, pyoderma nodosum and pyoderma gangrenosum. As far as we know, no acute generalized exanthematous pustulosis due to GSCF has been reported. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|